Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results
Perspective Therapeutics, Inc. (CATX)
Company Research
Source: GlobeNewswire
Lead program VMT-a-NET in neuroendocrine tumors continues to demonstrate a favorable tolerability profile with durable disease control and deepening of tumor response with longer follow-up, as reported at ASCO-GI 2026VMT-a-NET study on track to achieve nearly one year of follow-up in all 46 patients in Cohort 2 by mid-2026; analysis to inform patient selection strategy ongoingData across all dose levels in the VMT-a-NET program provide development optionality and support the build-out of a robust clinical evidence package for submission for presentation to more medical conferences and regulatory engagement in 2026Clinical updates for all three clinical programs are expected to be submitted for presentation at medical conferences throughout 2026Cash, cash equivalents and short-term investments of approximately $145M as of December 31, 2025, together with subsequent equity offering (net proceeds of ~$164 million), expected to be sufficient to fund current planned clinical milestones and
Show less
Read more
Impact Snapshot
Event Time:
CATX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CATX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CATX alerts
High impacting Perspective Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CATX
News
- Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Presentation at the AACR Annual Meeting 2026GlobeNewswire
- Perspective Therapeutics (NASDAQ:CATX) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.MarketBeat
- Perspective Therapeutics (NASDAQ:CATX) was given a new $16.00 price target on by analysts at Piper Sandler. They now have an "overweight" rating on the stock.MarketBeat
- New Treatment Modalities Are Reaching Cancers That Resisted Everything ElsePR Newswire
- Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial ResultsGlobeNewswire
CATX
Earnings
- 11/10/25 - Miss
CATX
Sec Filings
- 3/16/26 - Form 10-K
- 3/16/26 - Form 8-K
- 3/10/26 - Form SCHEDULE
- CATX's page on the SEC website